Aumolertinib (EQ143, HS-10296) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR-sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR. Aumolertinib was discovered by Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma), and EQRx has partnered with Hansoh Pharma on global development of aumolertinib.
EQRx holds the development and commercialization rights to aumolertinib outside of Greater China.
Hansoh Pharma holds the development and commercialization rights to aumolertinib within Greater China.
Aumolertinib is approved by the National Medical Products Administration (NMPA) of China for both first-line and second-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC.